Drug companies take years, even decades and burn a tremendous amount of cash to bring a drug to the market. Some drugs pass the FDA muster easily, while some struggle through the stringent review process. However, despite the regulatory setbacks, some companies exude a steely determination to bring their drugs to market.
The company we are profiling today is Aldeyra Therapeutics Inc. (ALDX), which, being twice denied FDA approval for its first-in-class investigational eye drop, Reproxalap, isn't backing down.
For comments and feedback contact: editorial@rttnews.com
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.